Quality of Life in Patients with Multiple Endocrine Neoplasia Type I (MEN1): Results from the Dutch MEN1 Study Group Abstract #1858

Introduction: Multiple Endocrine neoplasia type 1 (MEN1) is a hereditary tumor syndrome, characterized by an increased lifetime risk of benign and malignant endocrine tumors in various organs. Data on quality of life (QoL) in patients with MEN1 are scarce, whereas QoL is considered an important treatment outcome.
Aim(s): The primary aim was to evaluate the presence of MEN1-related fear for disease occurrence in MEN1 patients. The secondary aim was to assess the impact of MEN1 on health related QoL (HRQoL) and to identify variables that were significantly related to reduced QoL and cancer worry.
Materials and methods: A cross-sectional study was performed in which MEN1 patients completed the Short-Form 36 Health Related QoL and the Cancer Worry Scale.
Conference: 14th Annual ENETS conference (2017)
Category: ...none of the above
Presenting Author: MD Rachel van Leeuwaarde
Keywords: MEN1, QoL

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1765 Management of MEN1 Related Non-Functioning Pancreatic NETs: A Shifting Paradigm. Results from the Dutch MEN1 Study Group
Introduction: The evidence base when to operate MEN1 related non-functioning pancreatic neuroendocrine tumors (NF-pNETs) is meager.
Conference: 14th Annual ENETS conference (2017)
Category: Surgical treatment
Presenting Author: Drs. Sjoerd Nell
Keywords: MEN1
#1438 An Unusual Phenotype of Multiple Endocrine Neoplasia Type 1 with a Small Intestine Neuroendocrine Tumor Associated with Large Deletion of the MEN1 Gene
Introduction: Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant inherited tumor syndrome that is caused by germline mutations in the Menin suppressor gene on chromosome 11q13. Small intestine neuroendocrine neoplasias (SI-NEN) are currently not considered to be part of the phenotype of the MEN1-syndrome.
Conference: 13th Annual ENETS conference (2016)
Category: Clinical cases/reports
Presenting Author: MD Jerena Manoharan
#1769 Minimal Risk of Persistent or Recurrent Hypoglycemia after MEN1-Related Insulinoma Surgery. A Large International Cohort Study
Introduction: Current literature states that 15-30% of the MEN1 patients suffer from hypoglycemia after insulinoma surgery.
Conference: 14th Annual ENETS conference (2017)
Category: Surgical treatment
Presenting Author: Drs. Sjoerd Nell
Keywords: MEN1
#901 Impact of Long-Acting Octreotide in Patients with Early-Stage MEN1-Related Duodeno-Pancreatic Neuroendocrine Tumors
Introduction: Somatostatin analogues (SSA) represent one of the main therapeutic options in patients affected by functioning well-differentiated neuroendocrine tumors (NETs). There are no studies specifically focusing on NETs associated with Multiple Endocrine Neoplasia type 1 (MEN1).
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: MD Valeria Ramundo
#1207 A Novel MEN1 Gene Variant in a Sporadic Case of Multiple Endocrine Neoplasia Type 1
Introduction: Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disorder characterised by the occurrence of hyperparathyroidism, pituitary adenomas and duodeno-pancreatic neuroendocrine tumours (NETs). Germline mutations of the MEN1 gene are identified in up to 87% of MEN1 families and 82% of isolated MEN1 cases.
Conference: 12th Annual ENETS Conference (2015)
Category: Clinical cases/reports
Presenting Author: MD Donato Iacovazzo
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.